Marker Therapeut Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Marker Therapeut has an operating margin of -168.7%, meaning the company retains $-169 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -440.4% the prior year.
Marker Therapeut's revenue surged 99.1% year-over-year to $6.6M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Marker Therapeut carries a low D/E ratio of 0.19, meaning only $0.19 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 6.36, Marker Therapeut holds $6.36 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Marker Therapeut passes 2 of 9 financial strength tests. No profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Marker Therapeut generates $1.02 in operating cash flow (-$10.9M OCF vs -$10.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Marker Therapeut (MRKR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 25 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Marker Therapeut generated $6.6M in revenue in fiscal year 2024. This represents an increase of 99.1% from the prior year.
Marker Therapeut reported -$10.7M in net income in fiscal year 2024. This represents a decrease of 30.3% from the prior year.
Marker Therapeut earned $-1.19 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 26.6% from the prior year.
Marker Therapeut held $19.2M in cash against $0 in long-term debt as of fiscal year 2024.
Marker Therapeut had 11M shares outstanding in fiscal year 2024. This represents an increase of 20.2% from the prior year.
Marker Therapeut's operating margin was -168.7% in fiscal year 2024, reflecting core business profitability. This is up 271.7 percentage points from the prior year.
Marker Therapeut's net profit margin was -162.8% in fiscal year 2024, showing the share of revenue converted to profit. This is up 85.9 percentage points from the prior year.
Marker Therapeut invested $13.5M in research and development in fiscal year 2024. This represents an increase of 29.3% from the prior year.
MRKR Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2M+43.2% | $861K+146.7% | $349K-84.5% | $2.3M+92.6% | $1.2M-6.0% | $1.2M+17.7% | $1.1M+310.1% | $258K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $2.3M-43.8% | $4.2M+33.2% | $3.1M-38.4% | $5.1M+117.8% | $2.3M-9.3% | $2.6M-1.6% | $2.6M+28.0% | $2.0M |
| SG&A Expenses | $1.0M+8.3% | $945K-31.0% | $1.4M+33.3% | $1.0M-10.1% | $1.1M-6.3% | $1.2M-11.5% | $1.4M-2.5% | $1.4M |
| Operating Income | -$2.1M+49.9% | -$4.3M+7.5% | -$4.6M-19.4% | -$3.9M-67.3% | -$2.3M+9.5% | -$2.5M+13.2% | -$2.9M+8.2% | -$3.2M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$2.0M+50.2% | -$4.0M+9.7% | -$4.4M-15.9% | -$3.8M-75.0% | -$2.2M+8.4% | -$2.4M+14.6% | -$2.8M+6.0% | -$3.0M |
| EPS (Diluted) | $-0.12+58.6% | $-0.29+27.5% | $-0.40+2.4% | $-0.41-64.0% | $-0.25+7.4% | $-0.27+15.6% | $-0.32+5.9% | $-0.34 |
MRKR Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $21.7M+47.2% | $14.8M-13.1% | $17.0M-22.8% | $22.0M+88.6% | $11.7M-17.2% | $14.1M-17.7% | $17.1M-12.1% | $19.5M |
| Current Assets | $21.7M+47.2% | $14.8M-13.1% | $17.0M-22.8% | $22.0M+88.6% | $11.7M-17.2% | $14.1M-17.7% | $17.1M-12.1% | $19.5M |
| Cash & Equivalents | $17.6M+68.1% | $10.5M-23.6% | $13.7M-28.7% | $19.2M+146.0% | $7.8M-31.1% | $11.3M-25.1% | $15.1M-13.5% | $17.5M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $3.3M-21.8% | $4.3M+71.0% | $2.5M-27.8% | $3.5M+75.7% | $2.0M-14.4% | $2.3M-25.1% | $3.1M+10.6% | $2.8M |
| Current Liabilities | $3.3M-21.8% | $4.3M+71.0% | $2.5M-27.8% | $3.5M+75.7% | $2.0M-14.4% | $2.3M-25.1% | $3.1M+10.6% | $2.8M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $18.4M+75.3% | $10.5M-27.6% | $14.5M-21.9% | $18.6M+91.3% | $9.7M-17.7% | $11.8M-16.1% | $14.1M-15.9% | $16.7M |
| Retained Earnings | -$457.5M-0.4% | -$455.5M-0.9% | -$451.5M-1.0% | -$447.0M-1.4% | -$440.9M-0.5% | -$438.7M-0.5% | -$436.3M-0.6% | -$433.5M |
MRKR Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.7M-45.7% | -$1.9M+65.8% | -$5.5M-16.9% | -$4.7M-31.8% | -$3.6M+7.0% | -$3.8M-62.1% | -$2.4M-110.0% | -$1.1M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0 |
| Financing Cash Flow | $9.9M+9863783.0% | $100-80.2% | $505-100.0% | $14.9M+33294.4% | $45K-9.1% | $49K+856.1% | $5K-98.9% | $479K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
MRKR Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -173.3%+321.5pp | -494.8%+825.3pp | -1320.1%-1148.7pp | -171.5%+25.9pp | -197.4%+7.5pp | -204.9%+73.2pp | -278.1%+964.2pp | -1242.2% |
| Net Margin | -162.1%+304.2pp | -466.3%+807.3pp | -1273.6%-1103.2pp | -170.4%+17.1pp | -187.5%+4.8pp | -192.3%+73.0pp | -265.3%+892.3pp | -1157.6% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -9.2%+18.0pp | -27.2%-1.0pp | -26.2%-8.7pp | -17.4%+1.3pp | -18.8%-1.8pp | -17.0%-0.6pp | -16.4%-1.1pp | -15.3% |
| Current Ratio | 6.50+3.0 | 3.45-3.3 | 6.79+0.4 | 6.36+0.4 | 5.92-0.2 | 6.12+0.5 | 5.57-1.4 | 7.01 |
| Debt-to-Equity | 0.18-0.2 | 0.41+0.2 | 0.17-0.0 | 0.19-0.0 | 0.200.0 | 0.20-0.0 | 0.22+0.1 | 0.17 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Marker Therapeut's annual revenue?
Marker Therapeut (MRKR) reported $6.6M in total revenue for fiscal year 2024. This represents a 99.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Marker Therapeut's revenue growing?
Marker Therapeut (MRKR) revenue grew by 99.1% year-over-year, from $3.3M to $6.6M in fiscal year 2024.
Is Marker Therapeut profitable?
No, Marker Therapeut (MRKR) reported a net income of -$10.7M in fiscal year 2024, with a net profit margin of -162.8%.
What is Marker Therapeut's earnings per share (EPS)?
Marker Therapeut (MRKR) reported diluted earnings per share of $-1.19 for fiscal year 2024. This represents a -26.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Marker Therapeut's operating margin?
Marker Therapeut (MRKR) had an operating margin of -168.7% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Marker Therapeut's net profit margin?
Marker Therapeut (MRKR) had a net profit margin of -162.8% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Marker Therapeut's operating cash flow?
Marker Therapeut (MRKR) generated -$10.9M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Marker Therapeut's total assets?
Marker Therapeut (MRKR) had $22.0M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Marker Therapeut spend on research and development?
Marker Therapeut (MRKR) invested $13.5M in research and development during fiscal year 2024.
How many shares does Marker Therapeut have outstanding?
Marker Therapeut (MRKR) had 11M shares outstanding as of fiscal year 2024.
What is Marker Therapeut's current ratio?
Marker Therapeut (MRKR) had a current ratio of 6.36 as of fiscal year 2024, which is generally considered healthy.
What is Marker Therapeut's debt-to-equity ratio?
Marker Therapeut (MRKR) had a debt-to-equity ratio of 0.19 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Marker Therapeut's return on assets (ROA)?
Marker Therapeut (MRKR) had a return on assets of -48.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Marker Therapeut's cash runway?
Based on fiscal year 2024 data, Marker Therapeut (MRKR) had $19.2M in cash against an annual operating cash burn of $10.9M. This gives an estimated cash runway of approximately 21 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Marker Therapeut's Piotroski F-Score?
Marker Therapeut (MRKR) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Marker Therapeut's earnings high quality?
Marker Therapeut (MRKR) has an earnings quality ratio of 1.02x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Marker Therapeut?
Marker Therapeut (MRKR) scores 75 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.